Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital.
Indiana University School of Medicine, Indianapolis, IN.
J Glaucoma. 2022 Jul 1;31(7):479-487. doi: 10.1097/IJG.0000000000002027. Epub 2022 Mar 29.
Open angle glaucoma (OAG), characterized by structural changes to the optic nerve head and retinal nerve fiber layer, is a progressive multifactorial optic neuropathy and a leading cause of irreversible blindness globally. Currently, intraocular pressure is the only modifiable risk factor; however, others have been identified, including genetics and race. Importantly, OAG is much more prevalent in persons of African descent (AD) compared with those of European descent (ED). OAG patients of AD are also known to have a more severe course of the disease, a finding potentially explained by structural and/or vascular differences within eye tissues. In addition, disparities in treatment outcomes have been identified in OAG patients of AD. Specifically, prostaglandin analogues have been suggested to be more effective in patients of AD than in those ED, while beta-adrenergic receptors have been suggested to be less effective, although the evidence is inconsistent. AD has also been identified as a risk factor for trabeculectomy failure while laser trabeculoplasty has been conversely found to be very effective in lowering intraocular pressure in patients of AD. Alternative surgical options, including Ex-Press shunt implantation, viscocanalostomy, and canaloplasty are promising in equivalence but require further research to evaluate disparity in outcome properly. In addition to treatment outcomes, social disparities affecting clinical care also exist for AD persons in the form of reduced adherence, access, and choice. Overall, data suggest the need for properly designed prospective trials with AD populations as a primary focus to identify the potential mechanisms driving disparities in treatment and address overall potential bias in glaucoma management.
开角型青光眼(OAG)以视神经头部和视网膜神经纤维层的结构改变为特征,是一种进行性多因素视神经病变,也是全球不可逆转失明的主要原因。目前,眼内压是唯一可改变的危险因素;然而,其他因素也已被确定,包括遗传和种族。重要的是,与欧洲血统的人相比,非洲裔人(AD)患 OAG 的几率要高得多。众所周知,AD 人群的 OAG 患者疾病的病程更为严重,这一发现可能是由于眼部组织内的结构和/或血管差异造成的。此外,AD 人群的 OAG 患者的治疗结果也存在差异。具体来说,前列腺素类似物在 AD 患者中的疗效比 ED 患者更为显著,而β肾上腺素受体的疗效则较差,尽管证据并不一致。AD 也被确定为小梁切除术失败的危险因素,而激光小梁成形术则被发现对 AD 患者降低眼压非常有效。替代手术选择,包括 Ex-Press 分流植入、黏弹剂切开术和小管成形术,在等效性方面很有前景,但需要进一步的研究来正确评估结果差异。除了治疗结果外,AD 患者在临床护理方面还存在社会差异,表现为降低了依从性、可及性和选择。总的来说,数据表明需要针对 AD 人群进行精心设计的前瞻性试验,以确定导致治疗差异的潜在机制,并解决青光眼管理中的整体潜在偏见。